News | January 03, 2010

Trial Will Examine Stem Cell, Drug Delivery System

January 4, 2010 – The FDA's permission is sought to allow a safety and feasibility trial for the PHOENIX System, which allows tissue stimulation and injections of biologic or pharmacologic agents to the myocardium. The system is designed to treat patients with refractory angina.

Cardiogenesis Corp. today said it submitted an investigational device exemption (IDE) with the FDA. The PHOENIX System utilizes the thermoacoustic stimulated tissue zone created by a laser and introduces additional potent, therapeutic agents, including stem cells, into the myocardium to dramatically enhance the healing process.

The PHOENIX includes an integral CrystalFlex fiberoptic component consisting of 37, 100 µm diameter fibers, identical to the fiber optic component currently in use in the FDA approved Sologrip III and PEARL 5.0 hand pieces. The hand piece has been modified to include three 26-gauge needles positioned around the fiber optic fibers, which allow precise delivery of fluids, including stem cells, into the tissue surrounding the channels created by the fiber optic.

"To date I have successfully treated 18 patients utilizing the PHOENIX with bone marrow derived stem cells,” said Dr. Guillermo Reyes, department of cardiovascular surgery, Hospital Universitario La Princesa, Madrid, Spain. “These were patients with severe angina and not candidates for coronary bypass or percutaneous intervention. At follow up, all of the patients improved by at least two classes of angina, and one-half were angina free. Based on the published literature and my own experience, laser channeling has proven to be a valuable clinical option. This preliminary study suggests the addition of stem cells is synergistic and this combination therapy offers the potential to improve clinical results and expand the utility of this approach."

These results build upon the in vivo research demonstrating that PHOENIX increased stem cell survival in targeted heart muscle when compared to direct injection alone.

For more information: www.cardiogenesis.com

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init